Obstetric and Gynecologic Imaging

What Is the Best Imaging for Pretreatment Staging of Ovarian Cancer?

·
What Is the Best Imaging for Pretreatment Staging of Ovarian Cancer?

A 64-year-old woman presents to your gynecologic oncology clinic with a new diagnosis of high-grade serous ovarian carcinoma, confirmed by biopsy of a complex adnexal mass initially identified on ultrasound. She is otherwise healthy and is a candidate for primary cytoreductive surgery. Before proceeding to the operating room, you need to accurately stage her disease to determine the extent of peritoneal, nodal, and distant involvement, which will guide the surgical approach and inform her prognosis. This article details the American College of Radiology (ACR) recommended imaging workflow for this specific clinical scenario: pretreatment staging of ovarian cancer. For this presentation, the ACR rates `CT abdomen and pelvis with IV contrast` as *Usually appropriate*.

Who Fits This Clinical Scenario?

This guidance applies specifically to adult patients with a new, histologically confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not yet received any treatment. The primary goal of imaging in this context is to establish the baseline extent of disease (staging) to inform the initial treatment plan, which is typically primary debulking surgery or neoadjuvant chemotherapy.

This workflow is **not** intended for:
* **Initial evaluation of an undifferentiated adnexal mass:** That workup focuses on characterizing the mass and determining the likelihood of malignancy, often involving ultrasound and MRI as primary modalities. This article assumes the diagnosis of cancer is already established.
* **Post-treatment surveillance in an asymptomatic patient:** Imaging for routine follow-up after completion of primary therapy follows a different set of recommendations.
* **Evaluation for suspected recurrence:** Patients with rising tumor markers or new clinical symptoms concerning for recurrence require a distinct imaging strategy to identify and characterize recurrent disease.

Correctly identifying the clinical scenario is critical, as applying staging guidelines to a surveillance or recurrence setting can lead to inappropriate test selection.

What Diagnoses Are You Working Up in This Scenario?

While the primary diagnosis of ovarian cancer is known, staging imaging is a search for the *extent* of disease. The key clinical questions you are trying to answer involve identifying the specific patterns of spread common to ovarian cancer, which directly correspond to the FIGO (International Federation of Gynecology and Obstetrics) staging system.

**Peritoneal Metastases:** This is the most common and defining pattern of spread for ovarian cancer. The imaging study must be sensitive for detecting tumor implants on the peritoneal surfaces of the abdomen and pelvis. This includes omental caking (infiltration of the greater omentum), serosal implants on the bowel, liver capsule, spleen, and diaphragm, and the presence and volume of ascites. The extent of peritoneal disease is a primary determinant of resectability.

**Lymphadenopathy:** The cancer can spread through lymphatic channels to pelvic and retroperitoneal (paraaortic) lymph nodes. Identifying enlarged or suspicious nodes is crucial for accurate staging and surgical planning, as it may necessitate a lymphadenectomy.

**Distant Metastatic Disease:** While less common at initial presentation than peritoneal spread, ovarian cancer can metastasize to distant sites. The most frequent locations include the pleura (causing malignant pleural effusions), lung parenchyma, and the parenchyma of the liver and spleen. Staging imaging must include the chest to assess for these findings.

**Local Organ Invasion:** The primary pelvic tumor may directly invade adjacent structures such as the uterus, bladder, or rectosigmoid colon. Defining these relationships is important for planning potential en bloc resections.

Why Is CT of the Abdomen and Pelvis with IV Contrast the Recommended Study?

For the pretreatment staging of ovarian cancer, the ACR designates `CT abdomen and pelvis with IV contrast` as *Usually appropriate*. A `CT chest with IV contrast` is also rated *Usually appropriate* and is almost always performed concurrently to provide comprehensive staging of the chest, abdomen, and pelvis.

The rationale for this recommendation is grounded in CT’s ability to rapidly and accurately assess the key areas of disease spread. Intravenous contrast is essential, as it enhances the peritoneum, solid organs, and blood vessels, making tumor implants and metastases more conspicuous against background tissues. CT provides high-resolution anatomical detail that is critical for evaluating:
* **Peritoneal Disease:** IV-enhanced CT is highly effective at identifying omental caking, ascites, and peritoneal implants, especially those larger than 1 cm.
* **Nodal and Visceral Metastases:** It is the standard for detecting enlarged retroperitoneal and pelvic lymph nodes and for identifying parenchymal metastases in the liver and spleen.
* **Surgical Planning:** CT provides a detailed roadmap for the surgeon, highlighting areas of extensive disease (e.g., on the diaphragm or small bowel mesentery) that may predict suboptimal cytoreduction and favor a neoadjuvant chemotherapy approach.

**Alternative Studies and Their Ratings**

* **MRI abdomen and pelvis without and with IV contrast** is rated *May be appropriate*. While MRI offers superior soft tissue contrast for evaluating the primary pelvic tumor and local invasion, it is generally considered less sensitive than CT for detecting small-volume peritoneal and omental disease. It is also more time-consuming and may be less accessible. MRI is often reserved as a problem-solving tool, for instance, to clarify an indeterminate liver lesion seen on CT or for patients with a severe contraindication to iodinated CT contrast.
* **FDG-PET/CT skull base to mid-thigh** is also rated *May be appropriate*. While PET/CT is highly sensitive for metabolically active tumor, its spatial resolution can be a limitation for detecting the small, flat peritoneal implants characteristic of ovarian cancer. Its primary role is often reserved for evaluating suspected recurrence or clarifying equivocal findings from a staging CT, rather than as the initial staging modality.
* **Ultrasound** is rated *Usually not appropriate* for staging. While it is a cornerstone for initial detection and characterization of an adnexal mass, it cannot adequately assess for peritoneal, retroperitoneal, or distant disease.

The radiation dose for a contrast-enhanced CT of the abdomen and pelvis is moderate (☢☢☢ 1-10 mSv), a level considered acceptable given the critical information gained for cancer staging and treatment planning.

Once you’ve decided on the recommended study, our protocol guide covers the technical details. For technique, contrast parameters, and reading principles, see: CT Chest/Abdomen/Pelvis with IV Contrast.

What’s Next After CT? Downstream Workflow

The results of the staging CT directly influence the next steps in management, creating a clear decision tree for the gynecologic oncology team.

* **If the CT shows potentially resectable disease:** This typically includes disease largely confined to the pelvis and peritoneum without evidence of extensive upper abdominal involvement or distant metastases that would preclude an optimal cytoreduction (leaving no visible residual disease or nodules <1 cm). The patient is scheduled for primary debulking surgery, which includes hysterectomy, salpingo-oophorectomy, omentectomy, and resection of all visible tumor. * **If the CT shows extensive or unresectable disease:** Findings such as bulky upper abdominal disease (e.g., encasing the porta hepatis or spleen), extensive small bowel mesenteric involvement, or distant parenchymal metastases suggest that optimal cytoreduction is unlikely. In this case, the patient will typically undergo a biopsy to confirm the diagnosis (if not already done) and then proceed to neoadjuvant chemotherapy. The goal is to shrink the tumor burden to make a subsequent interval debulking surgery more successful. * **If the CT is indeterminate:** An equivocal finding, such as a non-specific liver lesion or an unusual pattern of nodal enlargement, can create a diagnostic dilemma. The next step depends on whether this finding would change management. If so, a problem-solving study like a contrast-enhanced MRI or an FDG-PET/CT may be ordered. Alternatively, a percutaneous biopsy of the suspicious lesion may be performed.The staging CT is a pivotal point in the patient's journey, providing the anatomical information needed to choose the most effective initial treatment strategy.

Pitfalls to Avoid (and When to Get Help)

Several common pitfalls can compromise the quality and utility of staging imaging in ovarian cancer.

* **Omitting IV Contrast:** A non-contrast CT is inadequate for staging. Peritoneal implants, small liver metastases, and nodal disease are often invisible without IV contrast enhancement. Always specify “with IV contrast” unless there is a severe contraindication.
* **Incomplete Imaging of the Chest:** Ovarian cancer frequently metastasizes to the pleura and mediastinal lymph nodes. Staging is incomplete without dedicated imaging of the chest, which should be performed at the same time as the abdomen/pelvis CT.
* **Misinterpreting Bowel as Disease:** Unopacified or fluid-filled loops of bowel can sometimes mimic peritoneal or mesenteric masses. While oral contrast protocols vary, ensuring good communication with the radiology department about the clinical question can help optimize the study.
* **Over-relying on Nodal Size:** While enlarged lymph nodes are suspicious, normal-sized nodes can still contain microscopic metastases. CT staging of nodal disease has known limitations in sensitivity.

If the CT report describes an indeterminate finding that would alter the decision between primary surgery and neoadjuvant chemotherapy, it is critical to escalate. This typically involves a discussion at a multidisciplinary tumor board with radiologists, surgeons, and medical oncologists to decide on the next best step, which may include further imaging or biopsy.

Related ACR Topics and Tools

This article is a deep dive into one specific clinical scenario. For a comprehensive overview of imaging for all related presentations, including surveillance and suspected recurrence, please consult our parent topic guide. You can also use the tools below to explore other scenarios, protocols, and radiation dose considerations.

Frequently Asked Questions

Why not use PET/CT as the first imaging test for staging ovarian cancer?

While FDG-PET/CT is very sensitive for metabolically active cancer, its role in initial staging is rated as ‘May be appropriate’ by the ACR, not ‘Usually appropriate’. This is because its spatial resolution may not be sufficient to detect the small, flat peritoneal implants that are characteristic of ovarian cancer spread. Contrast-enhanced CT provides superior anatomical detail of the peritoneum. PET/CT is more commonly used to investigate equivocal findings on a CT scan or in the setting of suspected recurrence.

Is MRI a better choice than CT for initial staging?

Not usually. MRI is rated ‘May be appropriate’. While it provides excellent detail of the primary pelvic tumor and its relationship to adjacent organs, it is generally considered less accurate and slower than CT for assessing the full extent of small-volume disease throughout the abdomen, particularly on the omentum and bowel surfaces. CT remains the workhorse for providing a comprehensive surgical roadmap. MRI is an excellent problem-solving tool, especially for indeterminate liver lesions or for patients who cannot receive iodinated CT contrast.

What imaging should be ordered if my patient has a severe allergy to iodinated CT contrast?

In cases of a severe allergy or other contraindication to iodinated contrast (e.g., severe renal impairment), MRI of the abdomen and pelvis with and without IV gadolinium-based contrast is the best alternative and is rated ‘May be appropriate’. It can provide much of the necessary staging information, though with the limitations noted above. An FDG-PET/CT is another option to consider in this situation, often in consultation with the radiology and oncology teams.

Is ultrasound sufficient for staging once the diagnosis of ovarian cancer is made?

No. Ultrasound is rated ‘Usually not appropriate’ for staging. Although it is essential for the initial detection and characterization of the adnexal mass, it cannot adequately visualize the peritoneal surfaces, retroperitoneal lymph nodes, or organs in the upper abdomen and chest. Comprehensive cross-sectional imaging with CT or MRI is required to accurately determine the stage of the disease.

Do I need to order oral contrast with the staging CT scan?

The use of oral contrast is institution-dependent. Some protocols use positive oral contrast (iodinated or barium) to opacify the bowel and distinguish it from adjacent masses. However, many modern protocols prefer neutral oral contrast (like water or Volumen) or no oral contrast at all, as positive contrast can sometimes create artifacts or obscure enhancing peritoneal implants. It is best to follow your institution’s standard protocol for oncologic staging CT.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 21, 2026